Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

The traditional Chinese medicine (TCM), Sheng-xue-xiao-ban, inhibits the angiogenesis in ovarian cancer in vitro

Enqi Kong¹, Chao Zhang², Xia Li³, Haiping Song⁴, Li Sun¹, Jing Tian⁵

¹Department of Gynecological Oncology, Qingdao Central Hospital, The Second Affiliated Hospital of Medical College of Qingdao University, Qingdao 266042, China; ²Department of Gynecological Oncology, Qingdao Central Hospital, The Second Affiliated Hospital of Medical College of Qingdao University, Qingdao 266042, People’s Republic of China; ³Department of Respiratory and Critical Medicine, Qingdao Central Hospital, The Second Affiliated Hospital of Medical College of Qingdao University, Qingdao 266042, People’s Republic of China; ⁴Department of Internal Medicine-Oncology, Qingdao Central Hospital, The Second Affiliated Hospital of Medical College of Qingdao University, Qingdao 266042, People’s Republic of China; ⁵Department of Gynecological Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin, China. North Huanhu West Road, Hexi Sports Institute, Tianjin,300060, China.

For correspondence:- Jing Tian Email: uyl66985@126.com

Accepted: 27 April 2022 Published: 31 May 2022

Citation: Kong E, Zhang C, Li X, Song H, Sun L, Tian J. The traditional Chinese medicine (TCM), Sheng-xue-xiao-ban, inhibits the angiogenesis in ovarian cancer in vitro. Trop J Pharm Res 2022; 21(5):995-1001 doi: 10.4314/tjpr.v21i5.13

© 2022 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: The traditional Chinese medicine (TCM), Sheng-xue-xiao-van (SXXB) is reported to be effective in treatment of thrombocytopenic purpura and chemotherapy-induced thrombocytopenia in clinical practices. The purpose of this study was to explore the functions of the SXXB Capsule in ovarian cancer in vitro.

Methods: The toxicity of the medicine was measured using CCK8 method in ovarian cancer cell lines A2780 and OC-3-VGH and also the human ovarian epithelial cell line IOSE80. The cells were treated using the DMSO-diluted SXXB solution with the concentration levels at0, 3.125 and 6.25 μg/ml. Western blot was applied to measure the VEGFA proteins in each group. Later, the cells treated with 0 and 25μg/ml SXXB solution for 48h were collected for supernatant. Then HUVECs were co-cultured with the supernatant. Migration and tube formation assays were performed thereafter.

Results: SXXB solution showed higher toxicity in ovarian cancer cells than in IOSE80. The protein levels of VEGFA were reduced as the SXXB concentrations increased in ovarian cancer cells but not in IOSE80. Migration and formed tubes were inhibited in HUVECs co-cultured with the supernatant collected from SXXB-treated ovarian cancer cells.

Conclusion: The SXXB Capsule might inhibit the angiogenesis in ovarian cancer in vitro.

Keywords: Angiogenesis; VEGFA; ovarian cancer; TCM